Feature | December 21, 2010

Report Presents New Recommendations on Sudden Cardiac Death Prediction and Prevention

December 21, 2010 - The outcome of a recent expert consensus workshop offers six specific research recommendations in high-priority areas for sudden cardiac death (SCD) prediction and prevention. In the United States, SCD claims more than 250,000 lives annually and is the cause of half of all heart disease deaths. The report, “Sudden Cardiac Death (SCD) Prediction and Prevention: Report from a National Heart, Lung and Blood Institute (NHLBI) and Heart Rhythm Society Workshop,” was published in the November 30th issue of Circulation, an official journal of the American Heart Association.

The purpose of the workshop was to discover emerging approaches for improved prediction and prevention of SCD. The expert panel, which consisted of 24 arrhythmia investigators, was asked to consider the three broad areas of basic, clinical and population sciences.

“With the support of HRS and NHLBI, the workshop provided a unique venue to tackle complex biomedical issues,” said Glenn Fishman, M.D., FHRS, at New York University. “It afforded experts the opportunity to challenge old concepts and debate new ideas, with the hope that our individual and collective creativity would provide a useful roadmap for future exploration.”

The report outlines the outcomes of the expert consensus workshop – identifying knowledge gaps and a series of six specific recommendations for future research approaches in order to improve the prediction and prevention of SCD. Recommendations (not prioritized):

• Establish multi-scale integrative models, utilizing molecular, cellular, organ-level, animal and computational approaches, and apply these models to determine arrhythmia mechanisms.
• Establish high throughput experimental strategies to rapidly determine the functional relevance of newly discovered genes associated with arrhythmias in humans.
• Develop novel risk stratification strategies to improve outcomes in select populations, including those with ICD indications.
• Facilitate study of well-phenotyped SCD and control populations, including understudied subgroups.
• Develop and validate a SCD risk score utilizing phenotypic, biologic and non-invasive markers.
• Establish strategies for SCD prevention that can be employed in the general population, targeting intermediate risk phenotypes.

“This report is critical to helping us identify limitations of current understanding and point the way to the most fruitful research avenues for the future,” said Douglas Packer, president of the Heart Rhythm Society, M.D., FHRS. “The Society is pleased to collaborate with the NHLBI and we will continue our efforts toward innovation in electrophysiology and the prevention of sudden death for years to come.”

For more information: www.hrsonline.org

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init